Document:

EX-10.1

 Exhibit 10.1 

AMENDED AND RESTATED STOCK REPURCHASE AGREEMENT 

THIS AMENDED AND RESTATED STOCK REPURCHASE
AGREEMENT (this “Agreement”) is made and entered into as of April 28, 2015, by and between Viking Therapeutics, Inc., a Delaware corporation (the “Company”), and
the individuals listed on EXHIBIT A attached hereto (each, a “Seller” and, collectively, the “Sellers”). Each of the Company and each Seller shall be referred to herein,
individually, as a “Party”, and the Company and such Sellers shall be referred to herein, collectively, as the “Parties.” 

RECITALS 
 A. The
Company and the Sellers previously entered into that certain Stock Repurchase Agreement, dated as of September 6, 2014 (the “Prior Repurchase Agreement”), pursuant to which, among other things, the Sellers agreed to sell
to the Company, and the Company agreed to purchase from the Sellers, certain shares of common stock of the Company (the “Common Stock”) as set forth in the Prior Repurchase Agreement. 

B. The number of shares of Common Stock to be purchased from the Sellers pursuant to the terms of the Prior Repurchase Agreement were based on
a formula that referenced the number of shares to be issued by the Company to Ligand Pharmaceuticals Incorporated and Metabasis Therapeutics, Inc. (collectively, the “Ligand Parties”) pursuant to that certain Master License
Agreement, dated May 21, 2014, by and among the Company and the Ligand Parties, as amended by that certain First Amendment to Master License Agreement, dated as of September 6, 2014, by and among the Company and the Ligand Parties (the
“Pre-Second Amendment License Agreement”). 
 C. On April 8, 2015, the Company and the Ligand Parties entered
into that certain Second Amendment to License Agreement, which amended the Pre-Second Amendment License Agreement (the Pre-Second Amendment License Agreement, as so amended, the “Amended License Agreement”). 

D. The Company and the Sellers desire to amend and restate the Prior Repurchase Agreement in its entirety as set forth herein in order to,
among other things, provide for a new formula for determining the number of shares to be repurchased from the Sellers that takes into account the terms of the Amended License Agreement. 

E. As of the date hereof, each Seller currently owns the shares of Common Stock set forth under “Owned Shares” on
EXHIBIT A attached hereto (the “Owned Shares”), which shares are vested as set forth on EXHIBIT A attached hereto. 

F. Each Seller has informed the Company that such Seller desires to sell the shares of the Owned Shares set forth under “Repurchased
Shares” on EXHIBIT A attached hereto (with respect to each Seller, such Seller’s “Repurchased Shares”) to the Company, at a purchase price of $0.00001 per Repurchased Share, and upon the other
terms and conditions set forth herein, on the date of the closing of the Company’s first underwritten public offering of Common Stock (the “Effective Date”). 

 G. The Company desires to repurchase the Repurchased Shares set forth under “Repurchased
Shares” on EXHIBIT A attached hereto from each Seller at a purchase price of $0.00001 per Repurchased Share, and upon the other terms and conditions set forth herein, on the Effective Date. 

NOW, THEREFORE, in consideration of the representations, warranties, covenants and agreements contained herein and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree that the Prior Repurchase Agreement shall be amended and restated in its entirety to read as follows: 

1. Repurchase and Sale of Stock. Each Seller agrees to, absolutely and unconditionally, convey, sell and transfer to the Company the
Repurchased Shares (with all rights, benefits and privileges), free and clear of any claims, liens, equities, pledges, security interests, commitments, charges, restrictions, prior assignments or other encumbrances, at the Closing (as defined
below), and the Company agrees to repurchase the Repurchased Shares (with all rights, benefits and privileges) from such Seller at the Closing, in each case in accordance with, and subject to, the terms and conditions set forth herein. 

2. Closing. The closing of the repurchase and sale of the Repurchased Shares described in Section 1 above (the
“Closing”) shall occur on the Effective Date as of immediately prior to, and contingent upon, the closing of the Company’s first underwritten public offering of Common Stock. The Parties intend for the Closing to take
place by exchange of facsimile or other electronically transmitted signature pages; provided, however, that if the Parties agree to an in-person closing, the Closing shall take place at a place mutually agreed upon by the Parties. 

3. Closing Deliveries; Payment; Withholding; Reissuance of Certificates. 

(a) Closing Deliveries. At the Closing, subject to the terms and conditions hereof, the Parties shall make the following deliveries:
(i) each Seller shall deliver to the Company the stock certificate(s) representing the Repurchased Shares being repurchased by the Company from such Seller (each, a “Tendered Certificate”), together with a duly executed
Stock Assignment Separate from Certificate in the form of EXHIBIT B attached hereto; and (ii) the Company shall pay to such Seller by check $0.00001 per Repurchased Share for the aggregate purchase price equal to the
product obtained by multiplying the number of Repurchased Shares by $0.00001 for all of the Repurchased Shares (each, a “Payment”). 

(b) Withholding. Each Seller hereby authorizes the Company to make any and all applicable withholdings of federal and state taxes and
other items that the Company may be required to deduct from the Payment to such Seller. 
 (c) Reissuance of Stock Certificate(s). As
soon as reasonably practicable after the Closing, the Company shall reissue to each Seller a stock certificate representing the shares of Owned Shares represented by any Tendered Certificate that were not repurchased by the Company pursuant to this
Agreement. 

  
 2 

 4. Representations of such Seller. Each Seller, severally and not jointly, hereby
represents and warrants to the Company as of the date hereof and as of the date of the Closing as follows: 
 (a) Such Seller is of legal
age, competent to enter into a contractual obligation, and a citizen of the United States of America. 
 (b) Such Seller has the full right,
power, authority and capacity to enter into and deliver this Agreement, to perform such Seller’s obligations hereunder and to consummate the transactions contemplated hereby. Such Seller has duly executed and delivered this Agreement and has
obtained the necessary authorization, if any, to execute and deliver this Agreement, to perform such Seller’s obligations hereunder and to consummate the transactions contemplated hereby, including, without limitation, obtaining the consent of
such Seller’s spouse, if any. This Agreement is a valid, legal and binding obligation of such Seller, enforceable against such Seller in accordance with its terms, except: (i) as limited by applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally; (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable
remedies; and (iii) to the extent the indemnification provisions contained in this Agreement may be limited by applicable federal or state securities laws. 

(c) The execution, delivery and performance by such Seller of this Agreement and the consummation by such Seller of the transactions
contemplated hereby do not and will not: (i) violate any law, statute, order, rule or regulation binding upon or applicable to such Seller or its properties or require any consent, approval, waiver, action, order or authorization of, notice to,
or registration or filing with, any person, entity or governmental body, agency or authority; or (ii) constitute a breach or violation of or default under (with or without notice or lapse of time or both) any indenture, mortgage, deed of trust,
contract, agreement or other instrument binding upon such Seller or its property. 
 (d) (i) Such Seller is the sole owner, beneficially and
of record, of the Repurchased Shares, and has good, valid and marketable title to the Repurchased Shares, free and clear of all claims, liens, equities, pledges, security interests, commitments, charges, restrictions, prior assignments and other
encumbrances of any nature whatsoever; (ii) the Repurchased Shares have not been pledged, hypothecated, encumbered, sold, assigned, endorsed, transferred, deposited under any agreement, hypothecated, pawned, pledged for any bank or brokerage
loan or otherwise, or disposed of in any manner by such Seller or on such Seller’s behalf; (iii) such Seller has not signed any power of attorney, any stock power or any other assignment or authorization respecting the Repurchased Shares
that is now outstanding and in force; and (iv) no person, trust, firm, corporation or other entity has any right, title, claim, equity or interest in, to or respecting the Repurchased Shares. Upon transfer of the Repurchased Shares by Seller to
the Company in accordance with this Agreement, the Company will own, and have good, valid and marketable title to, the Repurchased Shares, free and clear of any and all claims, liens, equities, pledges, security interests, commitments, charges,
restrictions, prior assignments or other encumbrances. 

  
 3 

 (e) There is no claim, action, suit, proceeding, arbitration, investigation or inquiry pending
or, to the best of such Seller’s knowledge, threatened, against or involving such Seller with respect to this Agreement, the transactions contemplated hereby, or the Repurchased Shares, before any federal, state, municipal, foreign, or other
court or governmental or administrative body or agency, or any private arbitration tribunal. 
 (f) Such Seller has not made any untrue
statement of a material fact related to a specific representation or warranty contained in this Agreement, nor has such Seller omitted to state any material fact necessary in order to make the specific statements contained in this Agreement not
misleading. 
 5. Representations of the Company. The Company hereby represents and warrants to each Seller as of the date hereof and
as of the date of the Closing as follows: 
 (a) The Company is a corporation duly organized, validly existing and in good standing under
the laws of the State of Delaware. 
 (b) The Company has the requisite corporate power and authority to execute and deliver this Agreement
and to carry out and perform its obligations under the terms of this Agreement. 
 (c) All corporate action on the part of the Company
necessary for the authorization, execution, delivery and performance of this Agreement by the Company, and the consummation of the transactions contemplated hereby, has been taken. The Agreement constitutes the valid and binding obligation of the
Company, enforceable in accordance with its terms, except: (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally; and
(ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies. 
 (d)
There is no claim, action, suit, proceeding, arbitration, investigation or inquiry pending or, to the best of the Company’s knowledge, threatened, against or involving the Company with respect to this Agreement, the transactions contemplated
hereby, before any federal, state, municipal, foreign, or other court or governmental or administrative body or agency, or any private arbitration tribunal. 

6. Further Acknowledgments and Agreements of such Seller. Each Seller hereby acknowledges and agrees as follows: 

(a) (i) the Repurchased Shares are not publicly traded or registered under the Securities Act of 1933, as amended, or any state securities
laws, and there is no public trading market or exchange for the Repurchased Shares; (ii) the purchase price being paid for the Repurchased Shares pursuant to this Agreement represents a mutually agreed upon price for the Repurchased Shares
determined by the Company and such Seller; (iii) the purchase price being paid for the Repurchased Shares pursuant to this Agreement is significantly less than the current fair market value of the Repurchased Shares as of the date hereof and as
of the Closing, and is less than the purchase price paid by such Seller to the Company for such Seller’s purchase of the Repurchased Shares; and (iv) such Seller has not relied on the Company or any of the Specified Parties (as defined
below) in agreeing to such price or in reaching such Seller’s decision to sell. 

  
 4 

 (b) the Payment being paid to such Seller hereunder shall constitute payment in full for the
Repurchased Shares and, after the payment of the Payment in accordance with the terms and conditions of this Agreement, such Seller shall not have any further right, title or interest in or to any of the Repurchased Shares. 

(c) (i) the Company has made available to such Seller information concerning the Company and the Repurchased Shares sufficient for such Seller
to make an informed decision regarding the sale of the Repurchased Shares to the Company and the transactions contemplated by this Agreement; (ii) the Company has provided such Seller an opportunity to ask questions and receive answers
concerning sale of the Repurchased Shares and the Company; and (iii) the Company has made available to such Seller the opportunity to obtain any additional information that the Company possesses deemed necessary by such Seller to verify the
accuracy of the information provided, and such Seller has received all such additional information requested. 
 (d) (i) such Seller has not
looked to, or relied in any manner upon, the Company or any of its Affiliates (as defined below), owners, directors, officers, employees, agents, representatives or outside counsel (collectively with the Company, the “Specified
Parties”) for advice regarding the legal, tax or financial consequences of the sale of the Repurchased Shares to the Company or the transactions contemplated by this Agreement; and none of the Specified Parties has made or is making any
representations or guarantees about any legal, tax or financial consequences or outcomes relating to the sale of the Repurchased Shares to the Company or the transactions contemplated by this Agreement; (ii) such Seller has had the opportunity,
and has been advised, to consult with such Seller’s own legal counsel, tax advisors, financial and other advisors in connection with the sale of the Repurchased Shares to the Company and the transactions contemplated by this Agreement;
(iii) such Seller is relying solely on such Seller’s own legal counsel, tax advisors, financial and other advisors with respect to the sale of the Repurchased Shares and the transactions contemplated by this Agreement; and (iv) such
Seller understands and agrees that such Seller (and not any of the Specified Parties) shall be responsible for such Seller’s own tax liability that may arise as a result of the sale of the Repurchased Shares and the transactions contemplated by
this Agreement. As used in this Agreement, “Affiliate” shall mean any person or entity that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with, such
entity. 
 (e) Except for the express representations and warranties contained in this Agreement, none of the Specified Parties has made any
representation or warranty to such Seller. 
 7. Indemnification. Such Seller agrees to indemnify and defend the Company, its
affiliates and each of their respective stockholders, officers, directors, employees and representatives (each person or entity being indemnified under this Section 7, an “Indemnitee”) against, and hold each Indemnitee
harmless from, any and all loss, damage, liability, payment and obligation and any and all reasonable expenses, including, without limitation, legal fees and costs (collectively, “Losses”), incurred, suffered, sustained or
required to be paid, directly or indirectly, by, or sought to be imposed upon, such Indemnitee, from and after the Closing, 

  
 5 

 
resulting from, related to or arising out of any material inaccuracy in or breach of any of the representations, warranties or covenants made by such Seller in or pursuant to this Agreement or in
any agreement, document or instrument executed and delivered pursuant hereto or in connection with the Closing or the transactions contemplated hereby. 

8. Release. Other than with respect to the representations and warranties made by each Party pursuant to this Agreement, (i) each
Seller hereby fully, finally and forever settles and releases any and all matters, claims, disputes or differences, known or unknown, suspected or unsuspected, which now exist, may exist, or hereto have existed among it and the Company with respect
to the Repurchased Shares arising prior to the Closing or on account of or arising out of any matter, cause or event occurring prior to the Closing or relating to the pre-Closing period, including, without limitation, any claim regarding
distributions arising from or relating to the ownership of the Repurchased Shares (collectively, the “Released Claims”), and (ii) the Company hereby fully, finally and forever settles and releases any and all matters,
claims, disputes or differences, known or unknown, suspected or unsuspected, which now exist, may exist, or hereto have existed among it and any Seller with respect to any Released Claims. With respect to the Released Claims, the Parties
specifically waive any rights or benefits they may have under Section 1542 of the California Civil Code, which provides as follows: 

A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of
executing the release, which if known by him or her must have mutually affected his or her settlement with the debtor. 
 9.
Miscellaneous. 
 (a) Survival. The representations, warranties and covenants contained in this Agreement shall survive the
execution and delivery of this Agreement, the Closing and the consummation of the transactions contemplated hereby. The covenants of the Company and such Seller contained in this Agreement shall survive the Closing in accordance with their
respective terms. None of the representations and warranties set forth in this Agreement shall be modified or affected by any investigation at any time made by or on behalf of any Party. All rights to indemnification contained in this Agreement
shall survive the Closing in accordance with their terms. 
 (b) Amendment; Waiver. Except as otherwise expressly provided herein,
any provision of this Agreement may be amended or modified and the observance of any provision of this Agreement may be waived (either generally or any particular instance and either retroactively or prospectively) only with the written consent of
the Parties or, with respect to a waiver, with the written consent of the Party against whom such waiver is sought. The failure of any Party to enforce its rights under this Agreement at any time for any period shall not be construed as a waiver of
such rights. 
 (c) Assignment. No Seller shall have any right or the power to assign or delegate any provision of this Agreement
except with the prior written consent of the Company (which may be withheld in the Company’s sole discretion). Except as provided in the preceding sentence, this Agreement shall be binding upon and shall inure to the benefit of the
Parties’ respective successors and assigns. 

  
 6 

 (d) Third Party Rights. This Agreement shall not create benefits on behalf of any other
person or entity not a Party, except for the Specified Parties and the Indemnitees, and this Agreement shall be effective only as among the Parties, their successors and permitted assigns, the Specified Parties and the Indemnitees. 

(e) Severability. If any provision of this Agreement or the application thereof to any person or entity or circumstance is held invalid
or unenforceable to any extent, the remainder of this Agreement and the application of that provision to other persons or entities or circumstances shall not be affected thereby, and that provision shall be enforced to the greatest extent permitted
by law. 
 (f) Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of
California applicable to contracts made and to be performed entirely in such state, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. 

(g) Dispute Resolution. 

(i) Any unresolved controversy, claim or dispute involving the parties directly or indirectly concerning this Agreement or the subject matter
hereof, including, without limitation, any questions concerning the scope and applicability of this Section 9(g), shall be finally settled by arbitration held in the County of San Diego, State of California (or such other location as the
Parties may mutually agree upon in writing) in accordance with the rules of commercial arbitration then followed by the American Arbitration Association or any successor to the functions thereof. The arbitration proceedings shall be conducted before
one (1) neutral arbitrator who shall be a member of any state bar who has been actively engaged in the practice of corporate and business law for at least fifteen (15) years. The arbitrator shall apply California law in the resolution of
all controversies, claims and disputes and shall have the right and authority to determine how his or her decision or determination as to each issue or matter in dispute may be implemented or enforced. Any decision or award of the arbitrator shall
be final, binding and conclusive on the parties, and judgment upon the award rendered by the arbitrator may be entered in any court having competent jurisdiction. The arbitrator’s compensation, and the administrative costs of the arbitration,
shall be borne by the parties in the manner set forth in the arbitration award, as determined by the arbitrator. 
 (ii) The Parties agree
that any action to compel arbitration pursuant to this Agreement may be brought in the appropriate Federal or state court in the State of California, and in connection with such action to compel the laws of the State of California shall control.
Application may also be made to such court for confirmation of any decision or award of the arbitrator, for an order of the enforcement and for any other remedies which may be necessary to effectuate such decision or award. The Parties hereby
consent to the jurisdiction of the arbitrator and of such court and waive any objection to the jurisdiction of such arbitrator and court. 

  
 7 

 (iii) Notwithstanding the foregoing provisions of this Section 9(g), nothing contained
herein shall require arbitration of any issue arising under this Agreement for which injunctive relief is successfully sought by any Party. Any action, suit or other proceeding initiated by any Party against another Party for injunctive relief or to
enforce this Section 9(g) or any decision or award of the arbitrator may be brought in any Federal or state court in the State of California having jurisdiction over the subject matter thereof as the Party bringing such action, suit or
proceeding shall elect. The Parties hereby submit themselves to the jurisdiction of any such court. 
 (h) Counterparts. This
Agreement may be executed in separate counterparts (including, without limitation, counterparts transmitted by facsimile or by other electronic means), each of which shall be an original and all of which when taken together shall constitute one and
the same agreement. 
 (i) Entire Agreement. This Agreement (together with the Exhibits hereto) contains the entire agreement and
understanding between the Parties as to the subject matter hereof and supersedes all prior and contemporaneous negotiations and agreements (whether written or oral) with respect thereto. 

(j) Remedies. The Parties agree and acknowledge that money damages may not be an adequate remedy for any breach of the provisions of
this Agreement and that any Party may in its sole discretion apply to any court of law or equity of competent jurisdiction (without posting any bond or deposit) for specific performance or other injunctive relief in order to enforce, or prevent any
violations of, the provisions of this Agreement. 
 (k) Confidentiality. Such Seller hereby agrees that, except as required by law,
such Seller shall not disclose or reveal to any person or entity the existence of, any information about, any other facts relating to, or any of the terms of, this Agreement (together with the Exhibits hereto), including, without limitation, the
status or any terms or conditions of this Agreement or any of the transactions contemplated hereby. Notwithstanding the foregoing, such Seller shall be entitled to disclose the Agreement to such Seller’s immediate family, attorneys or
accountants who agree to maintain the confidentiality thereof. 
 (l) Notices. All notices, demands or other communications to be
given or delivered under or by reason of the provisions of this Agreement will be in writing and will be deemed to have been given when delivered personally, mailed by certified or registered mail, return receipt requested and postage prepaid, or
sent via a nationally recognized overnight courier, or sent via email (receipt of which is confirmed) to the recipient. Such notices, demands and other communications will be sent to address indicated below: 

To the Company: 
 Viking
Therapeutics, Inc. 
 11119 North Torrey Pines Road, Suite 50 

San Diego, CA 92037 
 Attn: Brian
Lian, Ph.D. 
 Email: blian@vikingtherapeutics.com 

  
 8 

 To each Seller at the address set forth on EXHIBIT A attached hereto, 

or to such other address or to the attention of such other person as the recipient Party shall have specified by prior written notice to the sending Party.

 (m) Construction. Each Party acknowledges and agrees that it has been represented by legal counsel in the negotiation and delivery
of this Agreement and that this Agreement has been drafted and prepared through the efforts of each Party and the rule of construction that any vague or ambiguous terms are to be construed against the Party drafting such terms shall not be applied
to any Party. 
 (n) Further Assurances. Such Seller agrees on behalf of such Seller and such Seller’s assigns or successors in
interest that such Seller will, without further consideration, execute, acknowledge and deliver such other documents and take such further action as may be reasonably requested by the Company or necessary to carry out the purposes of this Agreement,
including, without limitation, those actions necessary to transfer to the Company good, valid and marketable title to the Repurchased Shares, free and clear of all claims, liens, equities, pledges, security interests, commitments, charges,
restrictions, prior assignments and other encumbrances. 
 (o) Expenses. Each Party shall bear its own costs and expenses in
connection with this Agreement and the transactions contemplated hereby, including all legal, accounting, financial advisory, consulting and all other fees and expenses of third parties. 

(p) Headings. Headings and captions are for convenience only and are not to be used in the interpretation of this Agreement. 

(q) Restatement. This Agreement amends and restates the Prior Repurchase Agreement in its entirety effective as of the date first set
forth above. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT
BLANK] 

  
 9 

 IN WITNESS WHEREOF, the Parties have executed this Amended and Restated Stock Repurchase
Agreement as of the date first set forth above. 
  

			
	“Company”
	
	Viking Therapeutics, Inc.
		
	By:		 /s/ Brian Lian, Ph.D.

	Name:		Brian Lian, Ph.D.
	Title:		CEO and President
	
	“Sellers”
		
	By:		 /s/ Brian Lian, Ph.D.

	Name:		Brian Lian, Ph.D.
		
	By:		 /s/ Michael Dinerman, M.D.

	Name:		Michael Dinerman, M.D.
		
	By:		 /s/ Isabelle Dinerman

	Name:		Isabelle Dinerman
		
	By:		 /s/ Rochelle Hanley, M.D.

	Name:		Rochelle Hanley, M.D.

 EXHIBIT A 
  

																																							
	 Seller
	 	 Contact
	 	Owned Shares	 	 	Repurchased Shares	 	 	Remaining Owned Shares	 
	 	 	Vested	 	 	Unvested	 	 	Total	 	 	Vested	 	 	Unvested	 	 	Total	 	 	Vested	 	 	Unvested	 	 	Total	 
	 Brian Lian, Ph.D.
	 	 c/o Viking Therapeutics, Inc.
 11119 North
Torrey Pines Road, Suite 50
 San Diego, CA 92037
 Email:
blian@vikingtherapeutics.com
	 	 	2,392,368	  	 	 	1,257,632	  	 	 	3,650,000	  	 	 	1,516,308	  	 	 	797,098	  	 	 	2,313,406	  	 	 	876,060	  	 	 	460,534	  	 	 	1,336,594	  
											
	 Michael Dinerman, M.D.
	 	 c/o Viking Therapeutics, Inc.
 11119 North
Torrey Pines Road, Suite 50
 San Diego, CA 92037
 Email:
mdinerman@vikingtherapeutics.com
	 	 	1,421,875	  	 	 	153,125	  	 	 	1,575,000	  	 	 	901,216	  	 	 	97,034	  	 	 	998,250	  	 	 	520,659	  	 	 	56,091	  	 	 	576,750	  
											
	 Isabelle Dinerman

                   
              
	 	 c/o Viking Therapeutics, Inc.
 11119 North
Torrey Pines Road, Suite 50
 San Diego, CA 92037
	 	 	473,948	  	 	 	51,052	  	 	 	525,000	  	 	 	300,395	  	 	 	32,355	  	 	 	332,750	  	 	 	173,553	  	 	 	18,697	  	 	 	192,250	  
											
	 Rochelle Hanley, M.D.
	 	 c/o Viking Therapeutics, Inc.
 11119 North
Torrey Pines Road, Suite 50
 San Diego, CA 92037
 Email:
rhanley@vikingtherapeutics.com
	 	 	125,000	  	 	 	125,000	  	 	 	250,000	  	 	 	79,226	  	 	 	79,227	  	 	 	158,453	  	 	 	45,774	  	 	 	45,773	  	 	 	91,547	  

  
 A-1 

 EXHIBIT B 

STOCK ASSIGNMENT SEPARATE FROM CERTIFICATE 

FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto Viking Therapeutics, Inc., a Delaware corporation (the
“Company”),                  shares of common stock of the Company standing in the name of the undersigned on the books of the Company represented by
certificate number(s)                 , of which                  shares of common stock
are vested on the date hereof and                  shares of common stock are unvested on the date hereof, and does hereby irrevocably constitute and appoint the
Secretary of the Company as attorney to transfer such stock on the books of the Company with full power of substitution. 
  

							
	Dated: May 4, 2015				By:		  

					Name:		  

  
 B-1EX-10.2

 Exhibit 10.2 

AMENDMENT NO. 1 TO FOUNDER COMMON STOCK PURCHASE AGREEMENT 

This Amendment No. 1 to Founder Common Stock Purchase Agreement (this “Amendment”) is made as of May 4,
2015, by and between Viking Therapeutics, Inc., a Delaware corporation (the “Company”), and Brian Lian, Ph.D. (“Purchaser”). 

RECITALS 

WHEREAS, the Company and Purchaser are parties to that certain Founder Common Stock Purchase Agreement,
made as of September 26, 2012 (the “Purchase Agreement”) pursuant to which the Company issued and sold to Purchaser, and Purchaser purchased from the Company, an aggregate of 2,650,000 shares (the “Purchased
Shares”) of the Company’s common stock, par value $0.00001 per share (“Common Stock”); 

WHEREAS, pursuant to that certain Amended and Restated Stock Repurchase Agreement, dated as of
April 28, 2015, by and among the Company, Purchaser, Michael Dinerman, M.D., Rochelle Hanley, M.D. and Isabelle Dinerman, the Company repurchased from Purchaser an aggregate of 1,679,596 of the Purchased Shares at a repurchase price of $0.00001
per share on the date hereof (the “Share Repurchase”); 
 WHEREAS, the Company
and Purchaser desire to amend the Purchase Agreement to reflect the vesting schedule for Purchaser’s outstanding unvested Vesting Shares after giving effect to the Share Repurchase; and 

WHEREAS, pursuant to Section 11(c) of the Purchase Agreement, no modification or amendment to the
Purchase Agreement shall be effective unless in writing signed by the parties to the Purchase Agreement. 
 NOW
THEREFORE, in consideration of the mutual covenants and agreements contained herein, and with reference to the above recitals, the parties hereby agree as follows: 

ARTICLE 1 
 AMENDMENT 

1.1 AMENDMENT TO SECTION 4(C) OF THE PURCHASE AGREEMENT. The second sentence of Section 4(c) of the Purchase Agreement is hereby
amended and restated in its entirety as follows: 
 “An additional (a) 51,528 of the Vesting Shares shall be released on each
one-month anniversary of the date of this Agreement through and including April 26, 2015, and (b) after giving effect to the repurchase of an aggregate of 1,679,596 of the Shares by the Company from Purchaser pursuant to that certain
Amended and Restated Stock Repurchase Agreement, dated as of April 28, 2015, by and among the Company, Purchaser and the other parties named therein (as may be amended or restated from time to time), (i) 18,869 of the Vesting Shares shall
be released on May 26, 2015 and on each one-month anniversary thereafter through and including August 26, 2015 and (ii) 18,868 of the Vesting Shares shall be released on September 26, 2015; provided, however, that
in each case such scheduled release from the Repurchase Option shall immediately cease as of the Termination Date.” 

 ARTICLE 2 

GENERAL PROVISIONS 
 2.1
CAPITALIZED TERMS. All capitalized terms in this Amendment, to the extent not otherwise defined herein, shall have the meaning assigned to them in the Purchase Agreement. 

2.2 CONTINUING EFFECTIVENESS. Except as modified by this Amendment, the Purchase Agreement shall remain in full force and effect and no party
by virtue of entering into this Amendment is waiving any rights it has under the Purchase Agreement, and once this Amendment is executed by the parties hereto, all references in the Purchase Agreement to “the Agreement” or “this
Agreement,” as applicable, shall refer to the Purchase Agreement as modified by this Amendment. 
 2.3 SUCCESSORS AND ASSIGNS. The
rights and benefits of this Amendment shall inure to the benefit of, and be enforceable by the Company and its successors and assigns. 

2.4 GOVERNING LAW. This Amendment and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be
governed, construed and interpreted in accordance with the laws of the State of California, without giving effect to principles of conflicts of law. 

2.5 COUNTERPARTS. This Amendment may be executed in one or two counterparts, including counterparts transmitted by facsimile or other
electronic transmission, each of which shall be deemed an original and all of which together shall constitute one instrument. 

[Signature Page Follows] 

  
 2 

 IN WITNESS WHEREOF, the
parties have executed this Amendment as of the date first above written. 
  

			
	THE COMPANY:
	
	 VIKING THERAPEUTICS, INC.,

a Delaware corporation

		
	By:		 /s/ Michael Dinerman, M.D.

	Name: 		Michael Dinerman, M.D.
	Title:		COO
	
	PURCHASER:
	
	 /s/ Brian Lian, Ph.D.

	BRIAN LIAN, PH.D.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]